TuisMRK • NYSE
add
Merck & Co Inc
Vorige sluiting
$99,85
Dagwisseling
$98,81 - $100,41
Jaarwisseling
$94,48 - $134,63
Markkapitalisasie
251,07 mjd USD
Gemiddelde volume
11,60 m
P/V-verhouding
20,81
Dividend-opbrengs
3,26%
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 16,66 mjd | 4,35% |
Bedryfskoste | 8,40 mjd | 48,81% |
Netto inkomste | 3,16 mjd | -33,47% |
Netto winsgrens | 18,95 | -36,26% |
Wins per aandeel | 1,57 | -26,29% |
EBITDA | 5,51 mjd | -21,97% |
Effektiewe belastingkoers | 22,71% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 14,59 mjd | 66,34% |
Totale bates | 117,53 mjd | 10,12% |
Totale aanspreeklikheid | 72,97 mjd | 11,53% |
Totale ekwiteit | 44,56 mjd | — |
Uitstaande aandele | 2,53 mjd | — |
Prys om te bespreek | 5,68 | — |
Opbrengs op bates | 9,48% | — |
Opbrengs op kapitaal | 13,29% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 3,16 mjd | -33,47% |
Kontant van bedrywe | 9,29 mjd | 20,40% |
Kontant van beleggings | -3,84 mjd | -1 051,20% |
Kontant van finansiering | -2,42 mjd | 43,20% |
Netto kontantverandering | 3,32 mjd | 12,11% |
Beskikbare kontantvloei | 7,42 mjd | 28,97% |
Meer oor
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Merck & Co. was originally established as the American affiliate of Merck Group in 1891. Merck develops and produces medicines, vaccines, biologic therapies and animal health products. It has several blockbuster products, including cancer immunotherapy, anti-diabetic medications, and vaccines for HPV and chickenpox, each generating significant revenue as of 2020.
The company is ranked 71st on the 2022 Fortune 500 and 87th on the 2022 Forbes Global 2000, both based on 2021 revenues. In 2023, the company’s seat in Forbes Global 2000 was 73. Wikipedia
Gestig
01 Jan. 1891
Webwerf
Werknemers
71 000
